TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04285073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting graft
Description: Implantation of e-PTFE Grafts inner surface-treated with paclitaxel as access for hemodialysis
Study: NCT01235260

Intervention type: OTHER
Intervention: Becaplermin nonusers
Description: A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)

Intervention type: DRUG
Intervention: Becaplermin users
Description: A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
Study: NCT01932905

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep rTMS
Description: Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep rTMS
Description: Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep rTMS
Description: Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
Study: NCT03814122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action-based cognitive remediation
Description: Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action-based cognitive remediation
Description: Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control Group
Description: Receive treatment-as-usual through regular early psychosis programming.
Study: NCT02623218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.
Study: NCT03366428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion
Study: NCT03410030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein-bound
Description: combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: combination therapy
Study: NCT05206162

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: theta burst stimulation
Description: TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: theta burst stimulation
Description: TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: theta burst stimulation
Description: TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.
Study: NCT02050321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
Study: NCT03050866

Intervention type: DRUG
Group type: OTHER
Intervention: Cabazitaxel
Description: 25mg/m2 q3w

Intervention type: OTHER
Group type: OTHER
Intervention: Antihistamine
Description: As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)

Intervention type: OTHER
Group type: OTHER
Intervention: Corticosteroid
Description: As intravenous premedication (dexamethasone 8 mg or equivalent)

Intervention type: OTHER
Group type: OTHER
Intervention: H2 antagonist
Description: As intravenous premedication (ranitidine or equivalent)

Intervention type: OTHER
Group type: OTHER
Intervention: Antiemetic
Description: Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
Study: NCT05183451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En- masse retraction and LLLT
Description: Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs. LLLT will be applied on days 0,3,7,14 from extraction then repeated biweekly till the end of retraction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: En- masse retraction without LLLT
Description: Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs.
Study: NCT02579005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patients with a living donor
Description: The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patients with a UCB donor
Description: The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
Study: NCT00957762

Intervention type: OTHER
Intervention: Body composition
Description: Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
Study: NCT02225457

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypercaloric diet
Description: Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet
Description: Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: polyphenols
Description: Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: placebo (for polyphenols)
Description: Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
Study: NCT03228043

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CAPEOX
Description: CAPEOX adjuvant chemotherapy for resectable colorectal
Study: NCT03606460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab Dose 1
Description: 300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab Dose 2 and Dose 3
Description: 600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48
Study: NCT00614276

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.

Intervention type: BEHAVIORAL
Intervention: TENDRILS
Description: Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.

Intervention type: BEHAVIORAL
Intervention: TENDRILS
Description: Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.

Intervention type: BEHAVIORAL
Intervention: TENDRILS
Description: Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Sexual Counseling Sessions
Description: Attend 3 sexual counseling sessions at M. D. Anderson.
Study: NCT04507698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Exercise Intervention
Description: INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC), randomised to either the supervised exercise arm or the self-directed exercise arm.
Study: NCT04316962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex cancer rehabilitation
Description: The program is conducted as group rehabilitation, organized by four hour weekly over 12 weeks (approximately 50 hours) with 8-10 participants in each group over three years. The program is located in Askøy Municipality's 'Health Central' and conducted by a multidisciplinary team.~The content of the program is based on prior research and clinical experience, consisting of five elements:~1. Individual goal-setting~2. Physical activity (2 hours/week) focusing on balance/coordination, cardio and strength.~3. Psychoeducation: Five teaching sessions and discussions focusing on physical activity, fatigue and late-effects, nutrition, coping, social support and work/studies. In addition, two sessions (first and last) will also include next of kin.~4. Individual follow-up: Mandatory session at the start and end of the program, otherwise based on individual request and need.~5. Peer support.
Study: NCT02308696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-to-Peer Support
Description: All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Community Services
Description: All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
Study: NCT02279277

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised physical therapy program prior to total knee replacement surgery
Study: NCT00905541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 40 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 80 mg simvastatin acute-on-chronic
Study: NCT03232450

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Subjects will receive 81 mg enteric coated aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Subjects will receive 81 mg enteric coated aspirin

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiovascular Implantable Device (CIED)
Description: All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular Implantable Device (CIED)
Description: All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gore Cardioform Septal Occluder
Description: The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
Study: NCT02218541

Intervention type: DEVICE
Group type: OTHER
Intervention: abutment margin 0.5 mm subgingival

Intervention type: DEVICE
Group type: OTHER
Intervention: abutment margin 1.5 mm subgingival
Study: NCT04965233

Intervention type: BEHAVIORAL
Intervention: DNA reports
Description: The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.

Intervention type: BEHAVIORAL
Intervention: Information reports
Description: Reports containing general information on eczema
Study: NCT05055687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058
Description: 2500mg、3000mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: empty bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058
Description: 500mg、1000mg、2000mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: empty bottle
Study: NCT03599583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOP-HPV prompts intervention
Description: This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
Study: NCT03256864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Everolimus
Description: In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Everolimus
Description: In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL.
Study: NCT00405262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac + bupivacaine
Description: 0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
Study: NCT01756313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser+Methylaminolevulinat
Description: It's a single arm study. Intervention as described in detailed description.
Study: NCT03314857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN XT THV with the NovaFlex+ delivery system
Description: Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
Study: NCT01202253

Intervention type: DRUG
Intervention: anidulafungin
Description: A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
Study: NCT02901730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 532nm laser group
Description: LPI with 532nm laser.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 561nm laser group
Description: LPI with 561nm laser.
Study: NCT04133116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03329924

Intervention type: OTHER
Intervention: Activity level measurement by accelerometer
Description: Eligible patients will wear an accelerometer to measure activity levels while in the ICU.

Intervention type: OTHER
Intervention: Activity level measurement by accelerometer
Description: Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
Study: NCT02299869

Intervention type: DEVICE
Group type: OTHER
Intervention: Verde (Competitor-control)
Description: contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Green (CVI-test)
Description: contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Cinza (Competitor-control)
Description: contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Grey (CVI-test)
Description: contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Esmeralda (Competitor-control)
Description: contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Jade (CVI-test)
Description: contact lens